COMP <GO>
STRO vs TARA // NET PROFIT MARGIN
Sutro Biopharma Inc. (NASDAQ) VS. Protara Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: STRO 2
— TARA 2
■ METRIC PARITY
LAST: $9.10 (-0.44%) • MKT CAP: $151.6M
net-margins
-60.00%
LAST: $2.48 (-1.59%) • MKT CAP: $148.9M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STRO VS. TARA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STRO | TARA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -34.70% | -0.30 | TARA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | STRO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.2 | 38.3 | -13.14 | TARA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $151.6M | $148.9M | $2.6M | STRO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STRO REV | TARA REV | STRO GROSS % | TARA GROSS % | STRO FCF | TARA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $102.5M | $0 | — | — | -$177.2M | -$56.5M |
| FY 2024 | $62.0M | $0 | — | — | -$191.5M | -$35.9M |
| FY 2023 | $153.7M | $0 | — | — | -$111.6M | -$37.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STRO // BETA —
TARA // BETA —